Daiichi Sankyo Company vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Daiichi Sankyo Company, Limited (4568.JP)

Q3 202626 Jun – 17 Sep 2026

▲3▼1

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and Strong Revenue

EU Approvals for Datroway and Enhertu Datroway received EU first-line TNBC approval, while Enhertu gained EU tumor-agnostic approval, triggering a $25M AstraZeneca milestone. These expand treatment options and validate the ADC platform.
These approvals are major regulatory wins that open new markets and drive revenue potential.
Enhertu Reimbursement and Trial Success Enhertu secured NHS England reimbursement for HER2-low breast cancer after earlier rejection and showed strong first-line lung cancer data. This improves patient access and supports future growth.
Reimbursement and positive trial results directly impact sales and market confidence.
Strong Q1 Revenue and Raised Guidance Q1 revenue jumped 21% to ¥574.7B, prompting raised full-year guidance. This reflects robust business performance and management confidence.
Revenue growth and guidance raise are key financial indicators that drive investor sentiment.
Reimbursement Uncertainty and Undisclosed Economics The NHS pricing deal could still fall through, and confidential discounts obscure the exact financial benefit of expanded access. These factors temper the positive outlook.
These risks could limit the financial upside from approvals and reimbursements.

August 202631 Jul – 17 Sep 2026

▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.
New approval directly expands the commercial opportunity for a key growth drug.
Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.
Guidance raise signals stronger-than-expected business momentum and earnings power.
Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.
Late-stage trial success increases the probability of a new major indication for Enhertu.
NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.
Reimbursement win widens patient access and commercial reach for a core drug.

Latest31 Jul – 17 Sep 2026

▲4

Daiichi Sankyo's cancer drugs win approvals, trials and NHS access

Datroway approved in EU for first-line TNBC Datroway became the first TROP2 antibody-drug conjugate approved in the EU for first-line triple-negative breast cancer, with a 5-month overall survival benefit. This opens a new, large market and supports the drug's rapid sales growth, pushing 4568.JP up.
New approval directly expands the commercial opportunity for a key growth drug.
Full-year guidance raised on 21% revenue jump First-quarter revenue rose 21% to 574.7 billion yen, led by Enhertu and Datroway, and management raised full-year revenue and profit forecasts. Stronger U.S. sales and favorable currency rates underpin the upgrade, boosting investor confidence in 4568.JP.
Guidance raise signals stronger-than-expected business momentum and earnings power.
Enhertu shows strong first-line lung cancer data Enhertu cut the risk of progression or death by 37% versus standard care in first-line HER2-mutant lung cancer, with median progression-free survival of 14.3 months. Positive phase 3 results raise the chance of expanded approval, adding to 4568.JP's long-term growth outlook.
Late-stage trial success increases the probability of a new major indication for Enhertu.
NHS England reimburses Enhertu for HER2-low breast cancer England's NHS reversed an earlier rejection and will fund Enhertu for about 1,000 women a year with HER2-low metastatic breast cancer. As co-developer, Daiichi Sankyo shares in the expanded access, though confidential discounts mean the exact financial benefit is unclear.
Reimbursement win widens patient access and commercial reach for a core drug.

July 202626 Jun – 24 Jul 2026

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.
New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.
Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.
New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.
NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.
New pricing agreement would unlock a major market and signal broader reimbursement momentum.
Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.
New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

26 Jun – 24 Jul 2026

▲4

Daiichi Sankyo's ADC Franchise Expands with EU Approvals and NHS Pricing Deal

Datroway EU First-Line TNBC Recommendation Datroway, a TROP2 antibody-drug conjugate, was recommended for EU approval as first-line treatment for metastatic triple-negative breast cancer. The trial showed a 5-month overall survival benefit and 43% reduction in disease progression risk. This opens a new market and boosts future revenue potential.
New regulatory milestone directly expands Daiichi Sankyo's oncology portfolio and revenue outlook.
Enhertu EU Tumor-Agnostic Approval and Milestone Enhertu became the first tumor-agnostic HER2-directed ADC approved in the EU, triggering a $25 million milestone payment from AstraZeneca. This broadens Enhertu's label to many cancer types, increasing its patient population and long-term sales potential.
New approval and immediate cash milestone reinforce Enhertu's blockbuster status and Daiichi Sankyo's earnings.
NHS Pricing Deal for Enhertu Nears AstraZeneca and Daiichi Sankyo are close to a pricing agreement with NHS England for Enhertu, which could make the drug available to nearly 1,000 women with breast cancer. A deal would expand access and add revenue, though it could still fall through.
New pricing agreement would unlock a major market and signal broader reimbursement momentum.
Enhertu Plus Pertuzumab EU First-Line Recommendation The EMA recommended Enhertu plus pertuzumab as first-line treatment for HER2-positive metastatic breast cancer, with a 44% reduction in progression risk and 40.7-month median progression-free survival. If approved, it would be the first new first-line option in over a decade.
New combination therapy recommendation expands Enhertu's use earlier in treatment, driving higher sales.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 20269 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 20269 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest9 Jul – 31 Jul 2026

▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.
This is the single biggest new event of the period and the main reason ALNY is moving right now.
Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.
It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.
Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.
This is a major new competitive development that initially drove the stock up and remains a positive force.
Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.
It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 202622 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 202622 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

22 Jun – 3 Jul 2026

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.
This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.
AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.
These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.
Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.
A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.
Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.
Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.